Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data |
Yu, Xiaokang
(School of Biology and Biological Engineering, South China University of Technology)
Liang, Jinsheng (School of Biology and Biological Engineering, South China University of Technology) Xu, Jiarui (Department of Laboratory Science, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine) Li, Xingsong (School of Biology and Biological Engineering, South China University of Technology) Xing, Shan (Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) Li, Huilan (Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) Liu, Wanli (Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center) Liu, Dongdong (Department of Laboratory Science, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine) Xu, Jianhua (Department of Laboratory Science, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine) Huang, Lizhen (School of Biology and Biological Engineering, South China University of Technology) Du, Hongli (School of Biology and Biological Engineering, South China University of Technology) |
1 | Fan T, Mao Y, Sun Q, Liu F, Lin JS, Liu Y, et al. Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection. Cancer Sci 2018;109:2897-906. DOI |
2 | Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. DOI |
3 | American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Oncol Pract 2007;3:336-9. DOI |
4 | Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015;16:804-15. DOI |
5 | Du M, Shi D, Yuan L, Li P, Chu H, Qin C, et al. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Rep 2015;5:10437. DOI |
6 | Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8. DOI |
7 | Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006. DOI |
8 | Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008;3:e3148. DOI |
9 | Wang K, Zhang S, Weber J, Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010;38:7248-59. DOI |
10 | Pigati L, Yaddanapudi SC, Iyengar R, Kim DJ, Hearn SA, Danforth D, et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010;5:e13515. DOI |
11 | Kayala MA, Baldi P. Cyber-T web server: differential analysis of highthroughput data. Nucleic Acids Res 2012;40:W553-9. DOI |
12 | Freres P, Wenric S, Boukerroucha M, Fasquelle C, Thiry J, Bovy N, et al. Circulating microRNA-based screening tool for breast cancer. Oncotarget 2016;7:5416-28. |
13 | Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P, et al. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem 2015;61:1098-106. DOI |
14 | Chang YY, Kuo WH, Hung JH, Lee CY, Lee YH, Chang YC, et al. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing. Mol Cancer 2015;14:36. DOI |
15 | Song C, Zhang L, Wang J, Huang Z, Li X, Wu M, et al. High expression of microRNA-183/182/96 cluster as a prognostic biomarker for breast cancer. Sci Rep 2016;6:24502. DOI |
16 | Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, et al. Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol 2014;35:7733-41. DOI |
17 | Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One 2014;9:e96228. DOI |
18 | Pan Y, Zhang J, Fu H, Shen L. miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. Onco Targets Ther 2016;9:6247-55. DOI |
19 | Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, et al. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 2013;34:163-9. DOI |
20 | Li J, Song ZJ, Wang YY, Yin Y, Liu Y, Nan X. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer. Genet Mol Res 2016;15(3):gmr8338. |
21 | Allaya N, Khabir A, Sallemi-Boudawara T, Sellami N, Daoud J, Ghorbel A, et al. Over-expression of miR-10b in NPC patients: correlation with LMP1 and Twist1. Tumour Biol 2015;36:3807-14. DOI |
22 | Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, et al. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013;139:223-9. DOI |
23 | Madhavan D, Peng C, Wallwiener M, Zucknick M, Nees J, Schott S, et al. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis 2016;37:461-70. DOI |
24 | Zhang G, Liu Z, Cui G, Wang X, Yang Z. MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol 2014;35:11137-45. DOI |
25 | Zhu J, Zheng Z, Wang J, Sun J, Wang P, Cheng X, et al. Different miRNA expression profiles between human breast cancer tumors and serum. Front Genet 2014;5:149. |
26 | Kodahl AR, Lyng MB, Binder H, Cold S, Gravgaard K, Knoop AS, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 2014;8:874-83. DOI |
27 | Xia M, Li H, Wang JJ, Zeng HJ, Wang SH. MiR-99a suppress proliferation, migration and invasion through regulating insulin-like growth factor 1 receptor in breast cancer. Eur Rev Med Pharmacol Sci 2016;20:1755-63. |
28 | Shimomura A, Shiino S, Kawauchi J, Takizawa S, Sakamoto H, Matsuzaki J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci 2016;107:326-34. DOI |
29 | Dai X, Fang M, Li S, Yan Y, Zhong Y, Du B. miR-21 is involved in transforming growth factor beta1-induced chemoresistance and invasion by targeting PTEN in breast cancer. Oncol Lett 2017;14:6929-36. |
30 | Doberstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, et al. miR-21-3p is a positive regulator of L1CAM in several human carcinomas. Cancer Lett 2014;354:455-66. DOI |